Join to View Full Profile
440 Binney StDana Farber Cancer InstituteBoston, MA 02115
Phone+1 617-632-2144
Fax+1 617-632-2140
Dr. Anderson is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityResidency, Internal Medicine, 1977 - 1980- Johns Hopkins University School of MedicineClass of 1977
Certifications & Licensure
MA State Medical License 1980 - 2027
MD State Medical License 1977 - 1980
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013, 2015
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013, 2015
- Elected Member Institute of Medicine, 2010
Clinical Trials
- SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma Start of enrollment: 1994 Jan 01
- Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2001 Nov 01
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Start of enrollment: 2004 Dec 15
Publications & Presentations
PubMed
- PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.Anaïs Schavgoulidze, Jian Cui, Jessica Encinas, Vanessa Katia Favasuli, Srikanth Talluri
Blood. 2026-06-03 - 2 citationsProteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.Ting Du, Teng Fang, Sindhu Pillai, Arghya Ray, Minxing Wang
Blood. 2026-05-14 - Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma.William A Wood, Shaji K Kumar, Emily A Semmel, Shandra James, Mark A Schroeder
Blood Advances. 2026-05-12
Journal Articles
- APRIL Signaling via TACI Mediates Immunosuppression by T Regulatory Cells in Multiple Myeloma: Therapeutic ImplicationsKenneth C Anderson, Nikhil Munshi, Paul Richardson, Chirag Acharya, Nature
- Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple MyelomaNikhil Munshi, Kenneth C Anderson, A Keith Stewart, Sagar Lonial, Blood
Abstracts/Posters
- Determining Resistance Mechanisms in BRAF-mutated Multiple MyelomaKenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaKenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple MyelomaKenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
CAR-T Followed by Bispecific Yields Durable Responses in Myeloma TrialSeptember 25th, 2025- Minimal Residual Disease Negativity in Myeloma Tied to Favorable Safety and Patient-Reported OutcomesSeptember 23rd, 2025
- From No Hope to a Potential Cure for a Deadly Blood CancerJune 3rd, 2025
Grant Support
- Targeting Myeloma Cell-Host Bone Marrow InteractionsNational Cancer Institute2010–2012
- Host-Tumor Cell Interaction In Myeloma: Therapeutic ApplicationsNational Cancer Institute2010–2012
- Administrative And Clinical SupportNational Cancer Institute2010–2012
- Molecular Sequelae Of Myeloma-Bone Marrow Interactions: Therapeutic ApplicationsNational Cancer Institute2009–2012
- Spore In MyelomaNational Cancer Institute2008–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
